[ad_1]
(CercleFinance.com) – AstraZeneca announced Monday that a phase III clinical trial evaluating an experimental antibody-drug conjugate in breast cancer had not shown statistical significance in terms of overall survival, which led to a drop in its share price on the London Stock Exchange.
These final results come after interim data, published in 2023, which had shown that datopotamab deruxtecan (Dato-DXd) had proven to be ‘statistically significant’ and ‘clinically relevant’ in improving progression-free survival of the disease in the treated population.
The study included patients with hormone receptor-positive (HR+) but HER2-negative or low breast cancer who had received prior endocrine therapy and at least one systemic treatment for the disease.
For Susan Galbraith, AstraZeneca’s head of oncology R&D, these results demonstrate the clinical value of datopotamab deruxtecan and encourage further development of the drug.
Developed with the Japanese Daiichi Sankyo, datopotamab deruxtecan is currently the subject of around twenty clinical trials in the context of several types of breast cancer.
The announcement overshadows Friday’s approval by the U.S. FDA of the first self-administered flu vaccine, a needle-free nasal spray called FluMist, developed by the drugmaker.
AstraZeneca also announced that the European Medicines Agency (EMA) CHMP has recommended the marketing of Fasenra in relapsed or refractory eosinophilic granulomatosis with polyangiitis (EGPA), a rare vascular disease that can damage organs.
The group’s shares fell by 0.9% on Monday morning on the London Stock Exchange, one of the biggest falls on the FTSE index, which was up 0.3% at the same time.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
[ad_2]
Source link -84